The heatmaps below depict the transduction efficiency of all 50 tested AAV capsids on all cell types/donors available to date.
Please select a cell type in the drop-down menu below to view the detailed results and navigate to the “Methods” page for a description of data generation.

Data presented on this website were generated by screening a panel of 50 of the most used, predominantly published, AAV vectors to evaluate their transduction efficiency on the herein described cell types.
AAVs were produced by transfecting an Adenoviral helper, respective rep/cap plasmids and a plasmid comprising an AAV2-ITR-flanked, self-complementary CMV-eGFP-SV40p(A) expression cassette into adherent HEK293H cells. After three days, cell pellets were collected and AAV particles were released from the cells by freeze/thaw cycles. Genomic DNA and remaining plasmids were digested by addition of Salt Active Nuclease before PEG-precipitating proteins, including AAVs. Following overnight resuspension of the PEG pellet, AAVs were purified over an iodixanol gradient to remove contaminating proteins and empty capsids. The virus-containing iodixanol fraction was concentrated and buffer exchanged. The concentrate was sterile filtrated, aliquoted, and stored at -80 °C for later use. Titers, purity and genome integrity of individual AAV batches were determined by droplet digital PCR, SDS-PAGE and agarose gel, respectively.
All 50 AAV vectors were subsequently arrayed on 96-well plates and screened on the various cell types shown on this homepage. Differences in transduction efficiencies were assessed by detecting the percentage of GFP-positive cells and the mean fluorescence intensities by high-content microscopy and flow cytometry. In addition to the percentage of GFP-positive cells and the GFP mean fluorescence intensity (MFI), also a combined “Activity score”, calculated by multiplying the % GFP-positive cells value with the GFP fluorescence intensity (% GFP-pos. * MFI/100) is reported. The Activity score is a simple composite measure for overall capsid performance, integrating both, transduction efficiency and the degree of transgene expression mediated by a given capsid.

Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
D-55216 Ingelheim am Rhein

Handelsregister
Registergericht Mainz HR A 22206

vertreten durch die Komplementärin Boehringer Ingelheim Deutschland GmbH

Geschäftsführung:
Dr. Sabine Nikolaus (Vorsitzende),
Martin Beck, Jan Faßbender, Christjan Knudsen, Andreas Krüger;

Vorsitzende des Aufsichtsrates: Dr. Elke Simon;
Sitz: Ingelheim am Rhein; Registergericht Mainz: HR B 23260

USt.Id.-Nr. DE 143290578

Telefon: +49 61 32 77 0
Telefax: +49 61 32 77 30 00
E-Mail: press@boehringer-ingelheim.com

Die Boehringer Ingelheim Pharma GmbH & Co. KG ist nicht bereit oder verpflichtet, an Streitbeilegungsverfahren vor einer Verbraucherschlichtungsstelle teilzunehmen.

Zuständige Aufsichtsbehörden
Standort Ingelheim am Rhein:
Landesamt für Soziales, Jugend und Versorgung in Mainz
Rheinallee 97 - 101
55118 Mainz

Standort Biberach an der Riss:
Regierungspräsidium Tübingen
Konrad-Adenauer-Straße 20
72072 Tübingen